Alzheimer’s disease target and drug discovery by leveraging multiomics and electronic health data
Open Access
- 8 October 2026
- journal article
- research article
- Published by Springer Nature in Nature Neuroscience
- p. 1-14
Abstract
Despite prolific genomic data from individuals with Alzheimer’s disease (AD), translation into treatments has lagged. Here we applied Mendelian randomization to multiple AD genome-wide association studies and functional multiomics datasets to nominate druggable targets, identifying 19 targets for individuals of European ancestry and 7 for African ancestry. This included epoxide hydrolase 2 (EPHX2), for which we identified a protective missense variant (p.Arg287Gln). Experiments in induced pluripotent stem cell-derived neurons and cerebral organoids from patients with AD validated the protective role of p.Arg287Gln via reduced levels of EPHX2 and phosphorylated tau (pTau-181). Pharmacological inhibition of EPHX2 improved cognitive performance in the 5xFAD mouse model of AD. Finally, by leveraging electronic health data from 111,680 patients with mild cognitive impairment, we identified 12 drugs associated with reduced AD incidence, including trazodone (targeting ADRA1A) and baclofen (targeting GABBR1). Thus, integrating multiomics data, functional validation and electronic health data identifies new approaches for treating AD.Keywords
Funding Information
- National Institute on Aging (U01AG073323)
- National Institute on Aging (R35AG71476, R25 AG083721-01)
- National Institute on Aging (P30AG072959)
- National Institute of Neurological Disorders and Stroke (RF1NS133812)
This publication has 78 references indexed in Scilit:
- Donanemab in Early Symptomatic Alzheimer DiseaseJAMA, 2023
- Population‐based discovery and Mendelian randomization analysis identify telmisartan as a candidate medicine for Alzheimer's disease in African AmericansAlzheimer's & Dementia, 2022
- Genome-wide meta-analysis for Alzheimer’s disease cerebrospinal fluid biomarkersActa Neuropathologica, 2022
- Combining evidence from Mendelian randomization and colocalization: Review and comparison of approachesThe American Journal of Human Genetics, 2022
- Tau interactome maps synaptic and mitochondrial processes associated with neurodegenerationCell, 2022
- Black and White individuals differ in dementia prevalence, risk factors, and symptomatic presentationAlzheimer's & Dementia, 2021
- Genetic control of the human brain proteomeThe American Journal of Human Genetics, 2021
- Novel Alzheimer Disease Risk Loci and Pathways in African American Individuals Using the African Genome Resources PanelJAMA Neurology, 2021
- African Genetic Diversity: Implications for Cytochrome P450-mediated Drug Metabolism and Drug DevelopmentEBioMedicine, 2017
- CD38 Dictates Age-Related NAD Decline and Mitochondrial Dysfunction through an SIRT3-Dependent MechanismCell Metabolism, 2016